Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure
Summary
DSX is faster, more user-friendly, and scalable for high-performance computing LANCASTER, Calif., January 12, 2023--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI). Dr. Paul B. Watkins, chair of the Scientific Advisory Board of the DILI-sim Initiative, remarked: "DILIsym has shown great value in accurately predicting liver safety liabilities of new drug candidates. The information from DILIsym modeling serves to help guide go/no-go decisions on major drug development projects, potentially avoiding the disastrous financial effects of failed clinical trials, or better, providing assurances that DILI will not be an insurmountable obstacle to FDA approval. • None A complete software redesign that includes command line and graphical interface options and server/cloud computing capability (HPGL) • None 2 new SimCohorts that include variability in susceptibility to liver injury and biomarker-related parameters (ALT and bilirubin) Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market, providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches.
Classifications
AskAI Classifications
LabelsLinked Companies
